Entero Healthcar Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹1,339Cr
- +29.5% YoY
- −1.5% QoQ
- Net profit
- ₹31Cr
- +47.6% YoY
- +6.9% QoQ
- Margin
- 3.6%
- +0.8 pp YoY
- −0.1 pp QoQ
Guidance rank: #9 of 30 in Retailing
See the sector's top 10 — free with your mobile number.
The short version
Targeting over 30% revenue growth in FY ‘26, similar or better than FY ‘25’s 30% growth. FY ‘26 revenue growth target: >30%, continuing the momentum from FY ‘25 (30% growth).
From Entero Healthcar's Q4 FY25 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Targeting over 30% revenue growth in FY ‘26, similar or better than FY ‘25’s 30% growth.
- FY ‘25 growth comprised 16% organic growth and remaining from acquisitions; organic growth is expected to continue at 1.5x to 2x the Indian Pharmaceutical Market (IPM) growth rate.
- IPM assumed growth is ~8%; therefore, organic growth is anticipated around 15%-16%.
- Full-year impact of last year’s acquisitions expected to add approximately Rs. 500 crores.
- New acquisitions in FY ‘26 expected to add over Rs. 400 crores in annualized revenues.
- Long-term plan includes doubling down on organic expansion via new pharmacies, hospitals, and increased wallet share.
- Growth strategy balanced between organic growth and margin-accretive inorganic acquisitions.
2 more points from Entero Healthcar's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Entero Healthcar said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Focus remains on inorganic growth through acquisitions; recently completed 10 acquisitions and pipeline continues.
- Investments largely in acquisitions to expand geographic footprint, product portfolio, and capabilities.
- Emphasis on operational efficiencies, technology-led solutions, and building a digitally integrated healthcare distribution platform.
2 more points from Entero Healthcar's call on capex
Create a free account to keep reading this call
Top-ranked in Retailing
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Entero Healthcar said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Discussion focuses on acquisitions, integration timelines, and revenue growth guidance.
- Prabhat Agarwal mentions a timeline of about two to two and a half months to close remaining acquisitions, aiming to complete sooner.
- Total consideration for acquisitions is confidential; multiples are guided between 5x to 7x EV/EBITDA.
2 more points from Entero Healthcar's call on order book
Create a free account to keep reading this call
Entero Healthcar — Quarterly revenue & net profit
Entero Healthcar Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,339 | 1,034 | +29.5% | 1,359 | -1.5% |
| Operating profit (EBITDA) | 49 | 29 | +69% | 50 | -2% |
| Operating margin | 3.6% | 2.8% | +0.8 pp | 3.7% | -0.1 pp |
| Profit before tax | 37 | 14 | +164.3% | 39 | -5.1% |
| Net profit (PAT) | 31 | 21 | +47.6% | 29 | +6.9% |
| EPS (₹) | 5.90 | 4.82 | +22.4% | 5.85 | +0.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.1K Cr, net profit ₹61 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Entero Healthcar's management said in earlier quarters
Others in Retailing this season
- Trent (Q4 FY25)
GST): ₹17,624 crore (Page 6) . Key concall takeaways from Trent Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Baazar Style (Q4 FY25)
Store additions planned around 40 to 50 stores in FY ’26, with 20% to 25% increase in store count. Key concall takeaways from Baazar Style Retail Ltd's Q4 FY25…
- V2 Retail (Q4 FY25)
Volume growth remains strong, with 43% growth in FY25, supported by increased store count and product acceptance. Key concall takeaways from V2 Retail's Q4…
- FSN E-Commerce (Q4 FY25)
Nykaa’s overall GMV grew 27% YoY in Q4 and 25% for the full year FY25, with net revenue growth at 24% YoY for the full year. Key concall takeaways from FSN…
Potential multibaggers · Q2 FY27
Potential multibaggers in Retailing
on management's own guidance
- Strong growth2
- Strong growth1
- Lenskart SolutionsGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Entero Healthcar and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Entero Healthcar Q4 FY25 results?
Targeting over 30% revenue growth in FY ‘26, similar or better than FY ‘25’s 30% growth. FY ‘26 revenue growth target: >30%, continuing the momentum from FY ‘25 (30% growth).
What is Entero Healthcar share price analysis?
Entero Healthcar currently shows a neutral. The stock trades at a P/E of 48.0 with a market cap of ₹6,196 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Entero Healthcar on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
